|
|
叉头盒蛋白M1、Polo样激酶1在子宫内膜癌中的表达及其临床意义
|
Abstract:
目的：探讨叉头盒蛋白M1 (FOXM1)和Polo样激酶(PLK1)在子宫内膜癌中的表达，并分析两者表达的相关性及其临床意义。方法：以免疫组织化学染色的方法检测FOXM1和PLK1分别在子宫内膜癌、不典型增生和正常子宫内膜组织中的表达水平，然后分析两者在子宫内膜癌中表达水平的相关性，以及两者分别与临床病理参数之间的关系。结果：1) FOXM1和PLK1在子宫内膜癌组织中的表达水平明显高于正常子宫内膜组织和不典型增生内膜组织(P < 0.05)。2) FOXM1的高表达与子宫内膜癌的FIGO分期和淋巴结转移相关(P < 0.05)，PLK1的高表达与子宫内膜癌的病理分级、FIGO分期和淋巴结转移相关(P < 0.05)。3) 子宫内膜癌组织中FOXM1和PLK1的表达呈正相关(r = 0.310, P = 0.030)。结论：FOXM1和PLK1可能在子宫内膜癌的进展过程中发挥重要作用，二者的相互作用具有成为子宫内膜癌诊断生物标志物的潜能。
Objective: This study aimed to investigate the expression levels of forkhead box M1 (FOXM1) and polo-like kinase 1 (PLK1) in endometrial carcinoma, analyze their correlation, and evaluate their clinical significance. Methods: Immunohistochemistry was employed to detect the expression of FOXM1 and PLK1 in endometrial carcinoma tissues, atypical hyperplasia endometrial tissues, and normal endometrial tissues. The correlation between FOXM1 and PLK1 expression in endometrial carcinoma and their associations with clinicopathological parameters were further analyzed. Results: 1) The expression levels of FOXM1 and PLK1 were significantly elevated in endometrial carcinoma compared to atypical hyperplasia and normal endometrial tissues (P < 0.05). 2) High expression of FOXM1 was associated with FIGO stage and lymph node metastasis in endometrial carcinoma (P < 0.05), while high expression of PLK1 was correlated with pathological grade, FIGO stage, and lymph node metastasis (P < 0.05). 3) A positive correlation was observed between FOXM1 and PLK1 expression in endometrial carcinoma tissues (r = 0.310, P = 0.030). Conclusion: FOXM1 and PLK1 may play critical roles in the progression of endometrial carcinoma. Targeting these molecules could serve as a potential diagnostic and therapeutic strategy for endometrial carcinoma.
| [1] | Crosbie, E.J., Kitson, S.J., McAlpine, J.N., Mukhopadhyay, A., Powell, M.E. and Singh, N. (2022) Endometrial cancer. The Lancet, 399, 1412-1428. https://doi.org/10.1016/s0140-6736(22)00323-3 |
| [2] | Marín-Jiménez, J.A., García-Mulero, S., Matías-Guiu, X. and Piulats, J.M. (2022) Facts and Hopes in Immunotherapy of Endometrial Cancer. Clinical Cancer Research, 28, 4849-4860. https://doi.org/10.1158/1078-0432.ccr-21-1564 |
| [3] | Khan, M.A., Khan, P., Ahmad, A., Fatima, M. and Nasser, M.W. (2023) FOXM1: A Small Fox That Makes More Tracks for Cancer Progression and Metastasis. Seminars in Cancer Biology, 92, 1-15. https://doi.org/10.1016/j.semcancer.2023.03.007 |
| [4] | Kim, M.Y., Jung, A.R., Kim, G.E., Yang, J., Ha, U., Hong, S., et al. (2019) High FOXM1 Expression Is a Prognostic Marker for Poor Clinical Outcomes in Prostate Cancer. Journal of Cancer, 10, 749-756. https://doi.org/10.7150/jca.28099 |
| [5] | Kopanja, D., Chand, V., O’Brien, E., Mukhopadhyay, N.K., Zappia, M.P., Islam, A.B.M.M.K., et al. (2022) Transcriptional Repression by Foxm1 Suppresses Tumor Differentiation and Promotes Metastasis of Breast Cancer. Cancer Research, 82, 2458-2471. https://doi.org/10.1158/0008-5472.can-22-0410 |
| [6] | Liang, S., Hsu, C., Song, H., Huang, Y., Kuo, C., Yao, X., et al. (2021) FOXM1 Is Required for Small Cell Lung Cancer Tumorigenesis and Associated with Poor Clinical Prognosis. Oncogene, 40, 4847-4858. https://doi.org/10.1038/s41388-021-01895-2 |
| [7] | Iliaki, S., Beyaert, R. and Afonina, I.S. (2021) Polo-like Kinase 1 (PLK1) Signaling in Cancer and Beyond. Biochemical Pharmacology, 193, Article ID: 114747. https://doi.org/10.1016/j.bcp.2021.114747 |
| [8] | Su, S., Chhabra, G., Singh, C.K., Ndiaye, M.A. and Ahmad, N. (2022) PLK1 Inhibition-Based Combination Therapies for Cancer Management. Translational Oncology, 16, Article ID: 101332. https://doi.org/10.1016/j.tranon.2021.101332 |
| [9] | Kalathil, D., John, S. and Nair, A.S. (2021) FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis. Frontiers in Oncology, 10, Article 626836. https://doi.org/10.3389/fonc.2020.626836 |
| [10] | Fischer, M., Schade, A.E., Branigan, T.B., Müller, G.A. and DeCaprio, J.A. (2022) Coordinating Gene Expression during the Cell Cycle. Trends in Biochemical Sciences, 47, 1009-1022. https://doi.org/10.1016/j.tibs.2022.06.007 |
| [11] | Sher, G., Masoodi, T., Patil, K., Akhtar, S., Kuttikrishnan, S., Ahmad, A., et al. (2022) Dysregulated FOXM1 Signaling in the Regulation of Cancer Stem Cells. Seminars in Cancer Biology, 86, 107-121. https://doi.org/10.1016/j.semcancer.2022.07.009 |
| [12] | Xu, G., Wang, J., Mao, X. and Xu, M. (2024) 17β-Estradiol Inhibits Oxidative Stress-Induced Apoptosis in Endometrial Cancer Cells by Promoting FOXM1 Expression. Cell Biochemistry and Biophysics, 82, 1243-1251. https://doi.org/10.1007/s12013-024-01277-x |
| [13] | Droog, M., Nevedomskaya, E., Kim, Y., Severson, T., Flach, K.D., Opdam, M., et al. (2016) Comparative Cistromics Reveals Genomic Cross-Talk between FOXA1 and Erα in Tamoxifen-Associated Endometrial Carcinomas. Cancer Research, 76, 3773-3784. https://doi.org/10.1158/0008-5472.can-14-1813 |
| [14] | Chen, J., Yang, P., Li, S. and Feng, Y. (2023) Increased FOXM1 Expression Was Associated with the Prognosis and the Recruitment of Neutrophils in Endometrial Cancer. Journal of Immunology Research, 2023, Article ID: 5437526. https://doi.org/10.1155/2023/5437526 |
| [15] | Feng, Y., Li, S., Zhang, R., et al. (2018) FOXM1 as a Prognostic Biomarker Promotes Endometrial Cancer Progression via Transactivation of SLC27A2 Expression. International Journal of Clinical and Experimental Pathology, 11, 3846-3857. |
| [16] | Hafez, A.M., Harb, O., M. Etman, W., Hamed, B., E Namour, A. and A. Abdelaziz, L. (2021) Forkhead Box M1 Over-Expression and Dachshund Homolog 1 Down—Regulation as Novel Biomarkers for Progression of Endometrial Carcinoma in Egyptian Patients. Współczesna Onkologia, 25, 107-117. https://doi.org/10.5114/wo.2021.106697 |
| [17] | Moore, X.T.R., Gheghiani, L. and Fu, Z. (2023) The Role of Polo-Like Kinase 1 in Regulating the Forkhead Box Family Transcription Factors. Cells, 12, Article 1344. https://doi.org/10.3390/cells12091344 |
| [18] | Weng Ng, W.T., Shin, J., Roberts, T.L., Wang, B. and Lee, C.S. (2016) Molecular Interactions of Polo-Like Kinase 1 in Human Cancers. Journal of Clinical Pathology, 69, 557-562. https://doi.org/10.1136/jclinpath-2016-203656 |
| [19] | Kawaguchi, K., Kohashi, K., Iwasaki, T., Yamamoto, T., Ishihara, S., Toda, Y., et al. (2023) Prognostic Value of Nuclear Morphometry in Myxoid Liposarcoma. Cancer Science, 114, 2178-2188. https://doi.org/10.1111/cas.15729 |
| [20] | Fu, Z., Malureanu, L., Huang, J., Wang, W., Li, H., van Deursen, J.M., et al. (2008) Plk1-Dependent Phosphorylation of Foxm1 Regulates a Transcriptional Programme Required for Mitotic Progression. Nature Cell Biology, 10, 1076-1082. https://doi.org/10.1038/ncb1767 |
| [21] | Poyil, P.K., Siraj, A.K., Padmaja, D., Parvathareddy, S.K., Thangavel, S., Alobaisi, K., et al. (2024) PLK1 and FOXM1 Expressions Positively Correlate in Papillary Thyroid Carcinoma and Their Combined Inhibition Results in Synergistic Anti‐tumor Effects. Molecular Oncology, 18, 691-706. https://doi.org/10.1002/1878-0261.13610 |
| [22] | Dibb, M., Han, N., Choudhury, J., Hayes, S., Valentine, H., West, C., et al. (2015) FOXM1 and Polo-Like Kinase 1 Are Co-Ordinately Overexpressed in Patients with Gastric Adenocarcinomas. BMC Research Notes, 8, Article No. 676. https://doi.org/10.1186/s13104-015-1658-y |
| [23] | Zhang, Z., Zhang, G. and Kong, C. (2016) FOXM1 Participates in PLK1-Regulated Cell Cycle Progression in Renal Cell Cancer Cells. Oncology Letters, 11, 2685-2691. https://doi.org/10.3892/ol.2016.4228 |
| [24] | Yu, F., He, H., Nastoupil, L.J., et al. (2022) Targetable Vulnerability of Deregulated FOXM1/PLK1 Signaling Axis in Diffuse Large B Cell Lymphoma. American Journal of Cancer Research, 12, 4666-4679. |
| [25] | Fan, W., Ma, H. and Jin, B. (2022) Expression of FOXM1 and PLK1 Predicts Prognosis of Patients with Hepatocellular Carcinoma. Oncology Letters, 23, Article No. 146. https://doi.org/10.3892/ol.2022.13266 |
